Hepatology International

Papers
(The H4-Index of Hepatology International is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?184
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study103
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines80
The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–204079
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy75
Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma66
Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial63
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients52
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis51
Current perspectives on the tumor microenvironment in hepatocellular carcinoma51
An international multidisciplinary consensus statement on MAFLD and the risk of CVD50
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort49
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?47
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial46
Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial46
Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL)45
A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC45
The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis43
Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial42
High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B42
The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention39
Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease37
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study37
Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC36
SARS-CoV-2 infection and liver involvement35
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)34
Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy34
Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis33
Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial33
Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease31
Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure30
A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes30
0.039859056472778